Peter-Phillip De Cruz

Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes

Matthew Peverelle, Sarang Paleri, Jed Hughes, Peter De Cruz, Paul J Gow

Journal article  |  2020  |  Inflammatory Bowel Diseases

BACKGROUND: The impact of inflammatory bowel disease (IBD) activity on long-term outcomes after liver transplantation (LT) for pri..

Luminal microbiota related to Crohn's disease recurrence after surgery

Amy L Hamilton, Michael A Kamm, Peter De Cruz, Emily K Wright, Hai Feng, Josef Wagner, Joseph JY Sung, Carl D Kirkwood, Michael Inouye, Shu-Mei Teo

Journal article  |  2020  |  Gut Microbes

BACKGROUND: Microbial factors are likely to be involved in the recurrence of Crohn's disease (CD) after bowel resection. We invest..

Ustekinumab is a Safe and Effective Biological Agent for Crohn's Disease in a Liver Transplant Patient

Matthew Peverelle, Khashayar Asadi, Peter De Cruz

Journal article  |  2020  |  Journal of Crohn's and Colitis

Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure

Emma Flanagan, Peter R Gibson, Emily K Wright, Gregory T Moore, Miles P Sparrow, William Connell, Michael A Kamm, Jakob Begun, Britt Christensen, Peter De Cruz, Edward Shelton, Damian Dowling, Jane M Andrews, Steven J Brown, Olga Niewiadomski, Mark G Ward, Ourania Rosella, Gennaro Rosella, Katerina V Kiburg, Alyson L Ross, et al.

Journal article  |  2020  |  Alimentary Pharmacology & Therapeutics

Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?

Tim Raine, Bram Verstockt, Peter De Cruz

Journal article  |  2020  |  The Lancet Gastroenterology & Hepatology

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

Samba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, Daniel Cheng, Jakob Begun, Charlotte Keung, Daniel Van Langenberg, Lena Thin, Tamara Mogilevski, Peter De Cruz, Graham Radford-Smith, Emma Flanagan, Sally Bell, Soleiman Kashkooli, Miles Sparrow, Simon Ghaly, Peter Bampton, Elise Sawyer, Susan Connor, Quart-ul-ain Rizvi, et al.

Journal article  |  2020  |  World Journal of Gastroenterology

BACKGROUND: Vedolizumab (VDZ), a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved for us..

Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?

Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg

Journal article  |  2020  |  Alimentary Pharmacology & Therapeutics

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail

Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg

Journal article  |  2020  |  Alimentary Pharmacology & Therapeutics

Using Ustekinumab to Treat Crohn's Disease-Related Orofacial Granulomatosis: Two Birds, One Stone

Robert Gilmore, Christopher FD Li Wai Suen, Tim Elliott, Peter De Cruz, Ashish Srinivasan

Journal article  |  2020  |  Inflammatory Bowel Diseases

Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach.

Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg

Journal article  |  2020  |  Gut